Clovis Oncology (CLVS) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology Announces First Quarter 2018 Operating Results
May 8, 2018 4:05 PM EDT$18.5M in Rubraca® sales for the first quarter of 2018, based on limited third-line BRCA-mutant ovarian cancer treatment label in U.S. All-comers and earlier-line ovarian cancer maintenance treatment indication approved in U.S. on April 6, 2018 CHMP adopted positive opinion for limited treatment indication in EU on March 23; Marketing Authorization by European Commission anticipated later this month European maintenance treatment filing for ovarian cancer planned for Q2 2018, potential CHMP opinion by year-end Initiated potential registrational trial (ATLAS) of Rubraca in advanced... More
